ReviewDisaster medicine and public health preparedness2025
Advanced Medical Countermeasures and Devices for Use During a Radiological or Nuclear Emergency.
Review in Disaster medicine and public health preparedness, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Oral connexin43-peptide-loaded milk extracellular vesicles mitigate lethal radiation injury while preserving tumour radiosensitivity.Cancer letters · 2026Article
- YK-4-250, a synthetic telmisartan-tempol conjugate: crystal structure of a stabilized free radical containing an angiotensin ATActa crystallographica. Section C, Structural chemistry · 2026Article
- Synthetic Preimplantation Factor (sPIF)* Improves Survival and GI Function in Acute Lethal Radiation Syndrome in a Clinically Relevant Murine Model.International journal of molecular sciences · 2026Article
- Article
- Lipidomics of longer-term effects in the murine model after exposure to mixed field radiation and combined infection.Metabolomics : Official journal of the Metabolomic Society · 2026Article
- YK-4-250 mitigates gastrointestinal radiation syndrome and promotes overall survival following partial body radiation injury.Scientific reports · 2026Article
- Radiomitigators: Breakthroughs in Post-Radiation Recovery.Antioxidants (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Since the early 2000s, the US Government has made purposeful investments to help ensure medical preparedness should a radiological or nuclear incident occur within its borders. This focused support of products to diagnose, mitigate, and treat radiation-induced bodily injuries that would be anticipated during a radiation public health emergency has involved many departments, ranging from multiple agencies within the Department of Health and Human Services to the Department of Defense. The intent of this manuscript is to convey information both on products that have been approved by the US Food and Drug Administration for radiation injuries during a radiation incident, as well as promising approaches under advanced stages of development. These products impact multiple organ systems (e.g., bone marrow, gastrointestinal tract, lungs, kidneys, skin) and have been tested for efficacy in a number of different small and large preclinical animal models. The successful development of these models, methods, products, and devices discussed herein demonstrate the importance of an intentionally collaborative, "one-government" approach to fostering radiation research, while also showcasing the need for critical public-private partnerships - all to ensure the safety of the public should the unthinkable occur.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.